MX2019004940A - Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. - Google Patents

Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.

Info

Publication number
MX2019004940A
MX2019004940A MX2019004940A MX2019004940A MX2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A
Authority
MX
Mexico
Prior art keywords
dkk
antibody
beta
cancer
catenin
Prior art date
Application number
MX2019004940A
Other languages
English (en)
Spanish (es)
Inventor
H Kagey Michael
A Sirard Cynthia
Original Assignee
Leap Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leap Therapeutics Inc filed Critical Leap Therapeutics Inc
Publication of MX2019004940A publication Critical patent/MX2019004940A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019004940A 2016-10-26 2017-10-26 Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. MX2019004940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413198P 2016-10-26 2016-10-26
PCT/US2017/058555 WO2018081437A1 (en) 2016-10-26 2017-10-26 Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Publications (1)

Publication Number Publication Date
MX2019004940A true MX2019004940A (es) 2019-09-26

Family

ID=60570180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004940A MX2019004940A (es) 2016-10-26 2017-10-26 Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.

Country Status (14)

Country Link
US (2) US11267876B2 (cg-RX-API-DMAC7.html)
EP (1) EP3532099A1 (cg-RX-API-DMAC7.html)
JP (2) JP7374765B2 (cg-RX-API-DMAC7.html)
KR (1) KR102701695B1 (cg-RX-API-DMAC7.html)
CN (1) CN110114087A (cg-RX-API-DMAC7.html)
AU (1) AU2017347822B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019008279A2 (cg-RX-API-DMAC7.html)
CA (1) CA3041325A1 (cg-RX-API-DMAC7.html)
IL (1) IL266199B2 (cg-RX-API-DMAC7.html)
MA (1) MA46673A (cg-RX-API-DMAC7.html)
MX (1) MX2019004940A (cg-RX-API-DMAC7.html)
RU (1) RU2019115946A (cg-RX-API-DMAC7.html)
SG (1) SG11201903602RA (cg-RX-API-DMAC7.html)
WO (1) WO2018081437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
AU2020216494A1 (en) * 2019-02-01 2021-08-12 Board Of Regents, The University Of Texas System Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof
US20220381786A1 (en) * 2019-09-19 2022-12-01 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
KR20220131223A (ko) * 2019-11-22 2022-09-27 리프 테라퓨틱스 인코포레이티드 Dkk-1 억제제를 사용하여 암을 치료하는 방법
WO2023143444A1 (zh) 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
EP4499126A4 (en) * 2022-03-24 2026-03-25 Translational Genomics Res Inst PEPTIDE INHIBITORS TARGETTING THE TBL1-BETA-CATENIN COMPLEX
CN118924886A (zh) * 2023-03-16 2024-11-12 郑州大学 肿瘤共享新抗原表位肽或其编码核酸的新用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
EP2190478B1 (en) 2007-08-24 2016-03-23 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
KR20120117621A (ko) 2009-05-07 2012-10-24 노파르티스 아게 딕코프-1 또는 딕코프-4 또는 둘 모두에 대한 결합 분자에 대한 조성물 및 사용 방법
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
JP6465790B2 (ja) * 2013-02-27 2019-02-06 第一三共株式会社 Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
EP3077546A4 (en) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
US20220381786A1 (en) 2019-09-19 2022-12-01 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
KR20220131223A (ko) 2019-11-22 2022-09-27 리프 테라퓨틱스 인코포레이티드 Dkk-1 억제제를 사용하여 암을 치료하는 방법
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
US20260077043A1 (en) 2022-07-12 2026-03-19 Leap Therapeutics, Inc. Combination therapy

Also Published As

Publication number Publication date
SG11201903602RA (en) 2019-05-30
AU2017347822B2 (en) 2025-01-16
AU2017347822A1 (en) 2019-05-09
EP3532099A1 (en) 2019-09-04
CA3041325A1 (en) 2018-05-03
KR102701695B1 (ko) 2024-08-30
RU2019115946A (ru) 2020-11-27
IL266199B2 (en) 2025-02-01
IL266199B1 (en) 2024-10-01
US20220289831A1 (en) 2022-09-15
JP2019533693A (ja) 2019-11-21
IL266199A (en) 2019-06-30
CN110114087A (zh) 2019-08-09
RU2019115946A3 (cg-RX-API-DMAC7.html) 2021-01-26
MA46673A (fr) 2019-09-04
JP7374765B2 (ja) 2023-11-07
WO2018081437A1 (en) 2018-05-03
US20190284264A1 (en) 2019-09-19
BR112019008279A2 (pt) 2019-07-09
US12319730B2 (en) 2025-06-03
JP2023133432A (ja) 2023-09-22
US11267876B2 (en) 2022-03-08
KR20190085935A (ko) 2019-07-19

Similar Documents

Publication Publication Date Title
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MY195110A (en) Antibodies to PD-1 and uses Thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
NZ631197A (en) Anti sez6 antibodies and methods of use
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
ZA201703241B (en) Anti-c5 antibodies and methods of use
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
MX379396B (es) Conjugados de pirrolobenzodiazepina y anticuerpo.
JO3714B1 (ar) تركيبات الجسم المضاد لـ cd70 و cd3
AR099465A1 (es) Anticuerpos anti-jagged1 y métodos de uso
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
NZ628314A (en) Cd47 antibodies and methods of use thereof
CR20160387A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblástica aguda.
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX392040B (es) Estandares de antigeno prostatico y sus usos.